Toro Neurovascular, Inc. appears in FDA device records as the applicant for aspiration and support catheters classified under 21 CFR 870.1250, and as assignee on a published patent application describing an aspiration catheter with a shaped tip. The documented record covers two 510(k) clearances and one patent publication; it does not establish ownership structure, manufacturing sites, customers or commercial status. [1][5][7]
Toro 71 Aspiration Catheter and Toro Aspiration Tubing
FDA record K262021 names Toro Neurovascular, Inc. as applicant for the Toro 71 Aspiration Catheter and Toro Aspiration Tubing, with a decision of Substantially Equivalent dated October 21, 2026, under product code NRY and regulation number 870.1250. The record lists the submission as a Traditional 510(k) received June 16, 2026, reviewed by the neurology panel with a cardiovascular advisory committee, and accompanied by a Summary. [1][4]
The FDA final-decision listing for October 21, 2026 carries the same K262021 entry, matching the applicant and device names in the underlying record. [3]
Toro 88 Superbore Catheter
An FDA clearance letter dated January 16, 2026 addresses Ryan Walker, Co-Founder and Chief Operating Officer, regarding K252297 for the Toro 88 Superbore Catheter, a Class II percutaneous catheter under 21 CFR 870.1250 with product codes QJP and DQY. The letter describes the device as a variable stiffness, single lumen catheter designed to introduce interventional devices into the vasculature, and lists predicate devices including the TracStar LDP Large Distal Platform and Zoom 88 Large Distal Platform. [5]
The corresponding 510(k) database entry records the submission type as Traditional, not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. [6]
Published patent application
US 2023/0248940 A1, published August 10, 2023, names Toro Neurovascular, Inc. as assignee and describes an aspiration catheter with an elongate flexible tubular body, a side wall and a distal tip, with a helical coil embedded in the side wall extending from the proximal end to a location offset proximally from the distal tip. The application, filed February 1, 2023, claims benefit of provisional application 63/307,150 filed February 6, 2022. [7]
Company-published technology description
Toro Neurovascular's own website describes MicroFlex technology as using reinforcement wires that bend freely and flex more than traditional catheters, with a footnote reading "Data on file." The same page states that Toro 88 enables physicians to reach further and references patients with large bore catheters located in the petrous segment or beyond; those statements are the manufacturer's published claims rather than FDA findings. [2]
